A new mouse model for the slow-channel congenital myasthenic syndrome induced by the AChR εL221F mutation

被引:14
|
作者
Chevessier, Frederic [1 ]
Peter, Christoph [1 ]
Mersdorf, Ulrike [1 ]
Girard, Emmanuelle [2 ]
Krejci, Eric [2 ]
McArdle, Joseph J. [3 ]
Witzemann, Veit [1 ]
机构
[1] Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany
[2] Univ Paris 05, UMR 8194, Ctr Etud Sensorimotr, F-75005 Paris, France
[3] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA
关键词
Neuromuscular junction; Slow channel congenital myasthenic syndrome; Acetylcholine receptor; Mouse model; Homologous recombination; ACETYLCHOLINESTERASE KNOCKOUT MICE; NEUROMUSCULAR-JUNCTION; NICOTINIC RECEPTOR; M2; DOMAIN; MUSCLE; ACTIVATION; SUBUNIT; TRANSMISSION; PLASTICITY; UNDERLIES;
D O I
10.1016/j.nbd.2011.10.024
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We have generated a new mouse model for congenital myasthenic syndromes by inserting the missense mutation L221F into the epsilon subunit of the acetylcholine receptor by homologous recombination. This mutation has been identified in man to cause a mild form of slow-channel congenital myasthenic syndrome with variable penetrance. In our mouse model we observe as in human patients prolonged endplate currents. The summation of endplate potentials may account for a depolarization block at increasing stimulus frequencies, moderate reduced muscle strength and tetanic fade. Calcium and intracellular vesicle accumulation as well as junctional fold loss and organelle degeneration underlying a typical endplate myopathy, were identified. Moreover, a remodeling of neuromuscular junctions occurs in a muscle-dependent pattern expressing variable phenotypic effects. Altogether, this mouse model provides new insight into the pathophysiology of congenital myasthenia and serves as a new tool for deciphering signaling pathways induced by excitotoxicity at peripheral synapses. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:851 / 861
页数:11
相关论文
共 50 条
  • [1] The defect in a slow channel myasthenic syndrome mutant, εL221F
    Hatton, C
    Chen, J
    Shelley, C
    Croxen, R
    Beeson, D
    Colquhoun, D
    JOURNAL OF PHYSIOLOGY-LONDON, 2000, 527 : 110P - 111P
  • [2] Slow-channel congenital myasthenic syndrome (SCCMS) caused by a novel mutation in the acetylcholine receptor (AChR) ε subunit
    Ohno, K
    Milone, M
    Brengman, JM
    Lo Monaco, M
    Evoli, A
    Tonali, PA
    Engel, AG
    NEUROLOGY, 1998, 50 (04) : A432 - A432
  • [3] Properties of the human muscle nicotinic receptor, and of the slow-channel myasthenic syndrome mutant εL221F, inferred from maximum likelihood fits
    Hatton, CJ
    Shelley, C
    Brydson, M
    Beeson, D
    Colquhoun, D
    JOURNAL OF PHYSIOLOGY-LONDON, 2003, 547 (03): : 729 - 760
  • [4] AChR channel blockade by quinidine sulfate reduces channel open duration in the slow-channel congenital myasthenic syndrome
    Fukudome, T
    Ohno, K
    Brengman, JM
    Engel, AG
    MYASTHENIA GRAVIS AND RELATED DISEASES: DISORDERS OF THE NEUROMUSCULAR JUNCTION, 1998, 841 : 199 - 202
  • [5] CLINICAL FEATURES OF THE SLOW-CHANNEL CONGENITAL MYASTHENIC SYNDROME
    Lashley, D.
    Burke, G.
    Beeson, D.
    Jayawant, S.
    Palace, J.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (11):
  • [6] Treatment of slow-channel congenital myasthenic syndrome with fluoxetine
    Harper, CM
    Fukodome, T
    Engel, AG
    NEUROLOGY, 2003, 60 (10) : 1710 - 1713
  • [7] Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome
    Zhu, Haipeng
    Grajales-Reyes, Gary E.
    Alicea-Vazquez, Vivianette
    Grajales-Reyes, Jose G.
    Robinson, KaReisha
    Pytel, Peter
    Baez-Pagan, Carlos A.
    Lasalde-Dominicci, Jose A.
    Gomez, Christopher M.
    EXPERIMENTAL NEUROLOGY, 2015, 270 : 88 - 94
  • [8] Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome
    Harper, CM
    Engel, AG
    ANNALS OF NEUROLOGY, 1998, 43 (04) : 480 - 484
  • [9] A transgenic mice for the novel αC418W mutation;: a model for Slow-Channel Congenital Myasthenic Syndrome
    Céspedese, K
    Segarra, J
    Fernández-Mongil, M
    Venza, CJ
    Nieves, A
    Rivera, Y
    Vázquez, R
    Tardy, F
    Ortiz-Acevedo, A
    Ramírez, R
    Gomez, C
    Lasalde-Dominicci, JA
    Rojas, LV
    BIOPHYSICAL JOURNAL, 2005, 88 (01) : 624A - 624A
  • [10] Characterization of novel slow-channel congenital myasthenic syndrome (SCCMS) mutation in transmembrane domain-2 (TMD2) of the AChR δ subunit
    Shen, XM
    Milone, M
    Banwell, B
    Engel, AG
    NEUROLOGY, 2006, 66 (05) : A58 - A58